2020 Jun 12
Ramiro Araújo,a José Dolores Aranda-Martínez,b and Gonzalo Emiliano Aranda-Abreuc,∗
SARS-Cov-2, whose symptoms include difficulty swallowing, coughing, diarrhea, and breathing failure, has caused the loss of many lives around the world. In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects of COVID-19.Key Words: Drugs, Amantadine, COVID-19
Amantadine, which I have heard called “Asclepion’s Trident”, is a drug whose therapeutic indications are divided into 3 specialties: Neurology, Psychiatry and Infectology. It is a small molecule, a monoamine, with interesting pharmacological effects.
It began to be used as a drug for humans in 1969 as a corrective medication for involuntary movement disorders and soon began to be used by psychiatry to control undesirable side effects caused by antipsychotic drugs (neuroleptics) and in neurology for the treatment of movement disorders, particularly Parkinson’s disease.
In 1976 it was approved by the FDA for the symptomatic and/or prophylactic treatment of influenza A in adults. It was one of the drugs studied (in vitro) that revealed its therapeutic potential, at the time of the SARS-Severe Acute Respiratory Syndrome-epidemic in 2002 (7).
Amantadine is well absorbed when administered orally, it is well tolerated by the digestive system and the dose normally recommended for an adult is 1 capsule of 100 mg, twice a day for at least 14 d which is the time the virus remains in the body.
Niech lekarze poczytają też:
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment
Sandra P. Smieszek,⁎ Bart P. Przychodzen, and Mihael H. Polymeropoulos
Observational study of people infected with SARS-Cov-2, treated with amantadine
- Gonzalo Emiliano Aranda-Abreu,
- José D. Aranda-Martínez,
- Ramiro Araújo,
- María Elena Hernández-Aguilar,
- Deissy Herrera-Covarrubias &
- Fausto Rojas-Durán
We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine.
In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days.
This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2.
Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.